Cardiotoxic effects of BRAF/MEK inhibition: an observational study
Background - BRAF/MEK inhibitors are a cornerstone of the therapy of BRAF-mutant cancers. Despite frequent use, the incidence of cardiovascular side effects is still unclear. Data on cancer therapy-related cardiac dysfunction (CTRCD), particularly using contemporary biomarker-inclusive definitions,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
17 January 2026
|
| In: |
European journal of cancer
Year: 2026, Volume: 233, Pages: 1-8 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2025.116182 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2025.116182 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804925010688 
|
| Author Notes: | Jannek Brauer, Daniel Scheidet, Sebastian Romann, Christina Zehender, Jessica Hassel, Norbert Frey, Lorenz H. Lehmann |
| Summary: | Background - BRAF/MEK inhibitors are a cornerstone of the therapy of BRAF-mutant cancers. Despite frequent use, the incidence of cardiovascular side effects is still unclear. Data on cancer therapy-related cardiac dysfunction (CTRCD), particularly using contemporary biomarker-inclusive definitions, remain limited. - Objectives - To assess the incidence and risk factors of CTRCD in patients receiving BRAF/MEK inhibitors, using the International Cardio-Oncology Society (ICOS) definitions, which include cardiac imaging and biomarker assessments. - Methods - A total of 75 patients treated with BRAF/MEK inhibitors underwent prospective cardiotoxicity monitoring with two follow-up visits at 90 days (IQR 36-137 days) and 199 days (IQR 115-266 days). Standardized evaluations included echocardiography with global longitudinal strain (GLS), high-sensitivity cardiac troponin T (hs-cTnT), and NT-proBNP measurements at baseline and follow-up visits. CTRCD was classified according to ICOS criteria. Baseline risk was stratified by European Society of Cardiology (ESC) risk categories. - Results - CTRCD occurred in 33 of 75 patients (44%), with 17% classified as mild, 23% moderate, and 4% severe. Baseline age, sex, BMI, and most cardiovascular risk factors were not significantly associated with CTRCD. Coronary artery disease was the only baseline variable associated with increased CTRCD (OR 11.0, p=0.029; univariate analysis), whereas elevated hs-cTnT, NT-proBNP, or reduced LVEF at baseline were not predictive. Absolute CTRCD numbers were highest in the high ESC-defined cardiovascular risk category group, while incidence peaked in the low-risk group. Other cardiac complications occurred in 41 patients (55%). - Conclusions - CTRCD is frequent among patients treated with BRAF/MEK inhibitors. Traditional cardiovascular risk factors were not predictive, although coronary artery disease emerged as a strong risk marker. These findings highlight the need for dynamic surveillance strategies. |
|---|---|
| Item Description: | Online verfügbar: 12. Dezember 2025, Artikelversion: 19. Dezember 2025 Gesehen am 16.02.2026 |
| Physical Description: | Online Resource |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2025.116182 |